Opioid Litigation: Drug Mfrs. Lose Bid To Limit Data Disclosure; First Trials Set For March

US court orders firms to release information on all opioid products ever classified as Schedule II from one year prior to launch date; government, manufacturers oppose public disclosure of DEA distribution data.

White prescription pharmaceutical pills on map of United States

The US court overseeing multidistrict opioid litigation has shot down requests by manufacturers to limit the amount of information they must turn over in discovery, ordering the production of data on generic as well as branded products going back one year prior to their launch date. Defendants also must produce data that was previously made available in personal injury cases.

Special Master David Cohen issued a June 30 discovery ruling on several disputed issues. The ruling provides insight into...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Marketing & Advertising

More from Compliance